Exhibitors Search
유씨아이테라퓨틱스
Booth no.
E41
|
Exhibition
|
| |
|---|---|
|
Country
|
| Korea, South |
|
Address
|
|87 Cheongam-ro, Nam-gu, Pohang-si, Gyeongsangbuk-do, Republic of Korea |
|
Tel
|
|031-522-5315 |
|
Exhibits
|
| Next-generation CAR-NK immunotherapy with enhanced tumor microenvironment control and dual-target functionality |
|
Company Type
|
| |
Exhibitor Information
UCI Therapeutics is an innovative biotech company focused on developing next-generation anti-cancer immune cell therapies, particularly CAR-NK (Chimeric Antigen Receptor-Natural Killer cell) therapies. Overcoming the limitations of existing immuno-oncology drugs, it presents new possibilities for treating recurrent and refractory cancers, accelerating commercialization based on robust R&D capabilities. Specifically, through its differentiated approaches of ‘dual-specificity antibodies’ and ‘tumor microenvironment modulation,’ it provides a new treatment option that is safe and offers reduced treatment cost burdens.
Exhibit/Technology Introduction (General)
UCI-101 is a CD19/CD22 dual-specificity CAR-NK that fundamentally prevents recurrence caused by loss of the CD19 antigen on cancer cells following existing CD19 CAR-T therapy. UCI-112 is a CAR-NK that simultaneously secretes anti-MSLN CAR and TGF-beta signaling inhibitory peptides.
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : Next-generation CAR-NK immunotherapy with enhanced tumor microenvironment control and dual-target functionalityThis technology is a next-generation immunotherapy agent, specifically an allogenic, off-the-shelf CAR-NK cell therapy developed through genetic engineering. It targets blood cancers with a “bi-specific CAR-NK” approach, simultaneously secreting both cancer-targeted CARs and TME-modulating peptides.
KYUNGYON EXHIBITION CORP.
